The researchers also compared semaglutide with liraglutide and found a significant difference favouring semaglutide when used in doses ≥0.2 mg per day, compared with 3.0mg per day of liraglutide.
A related Comment notes that GLP-1 analogues are a novel development in the therapeutic area of obesity, with as yet no published large-scale trials comparing weight loss outcomes between one or more GLP-1 analogues in conjunction with other antidiabetic agents. The authors say that “it is possible the re-orientation of the antidiabetic treatment regimen to promote secondary weight loss could have a major impact on the natural history of early type 2 diabetes”.